This cohort study has several limitations: (1) not all the known NSAbs that have been reported to be associated with neurological diseases were tested by CBA in this study [for instance, not tested were antibodies to D2DR, mGluR5, mGluR1, neurexin-3α, IgLON5, DNER (Tr), Glycine receptor and amphiphysin]. This evidence concerns the gene GRM1 and nervous system disorder.